The Efficacy Analysis to Surgical Resection of Primary Liver Cancer Adjuvant Transarterial Chemoembolization in Ningxia

Objetive:(1) Master the status of primary liver cancer recurrence rate and survival rateof surgical treatment and postoperative adjuvant TACE treatment from January1997toJanuary2007in ningxia， And explore liver cancer prophylactic hepatic arterialchemoembolization (TACE) on the survival rate and tumor recurrence rate of patients withprimary liver cancer;（2）Analysis of relatively independent factors affecting the Ningxiaregion of primary liver cancer prognosis.Methods:1.Retrospective analysis of1997January to2007January in NingxiaMedical University general hospital patients， the preoperative diagnosis of primaryhepatocellular carcinoma，postoperative pathology confirmed hepatocellular carcinoma casescomplete data on225patients，TACE was given in105cases (chemoembolization group).Nothing in124cases (control group). The patients of two groups postoperative l-，2-，3-，5-year survival rate and tumor recurrence rate of the were compared.2. Cases subdivided intorelapse low-risk group， the recurrence of high-risk groups based on tumor diameter，number and presence of endoscopic tumor thrombus. Study the impact of adjuvant TACE forThe patients of two groups postoperative l-，2-，3-，5-year survival rate as well as the recent(≤2years)，and long-term (>2years) recurrence.3. Relatively independent factors affect theNingxia region of primary liver cancer prognosis analysis by Cox regression model.Results:1. To the simple excision patients， the l-，2-，3-，5-year survival rate (SR) and relapse rate was80.8%，56.4%，32.1%，15.4%and28.2%，42.3%，64.1%，89.7%;To thepostoperative adjuvant TACE treatment of patients，the l-，2-，3-，5-year survival rate (SR)and Relapse rate was84.7%、61.0%、49.2%、30.5%和22.0%、37.3%、45.8%、69.5%。There was no statistical difference between the two groups in survival and Relapse rate of theRecent (≤2years)(1og-rankP>0.05)，and there was statistical difference in survival，recurrence rate of Long-term (>2years)(1og-rankP<0.05).2.To the TACE group andnon-TACE group of relapse low-risk，the l-，2-，3-，5-year survival rate (SR) was95.0%、80.0%、67.5%、52.5%和92.7%、80.5%、70.7%、53.7%， There was no statistical differencebetween the two groups in survival rate(1og-rankP>0.05); To the TACE group andnon-TACE group of the recurrence of high-risk， the l-，2-，3-，5-year survival rate (SR)was88.0%、77.3%、61.3%、42.7%和83.8%、66.2%、44.6%、27.0%，There was statisticaldifference between the two groups in survival rate(1og-rankP<0.05);3. Multivariate analysisrevealed that independent factors affect the prognosis of primary liver cancer is cirrhosis，treatment modalities，portal vein thrombosis，tumor capsule，UICC stage，the number ofcancer nodules，pathological typeConclusions:1. the postoperative adjuvant transcatheter arterial chemoembolizationtreatment can significantly after long-term (>2years) recurrence rate and improve survival.2.Cirrhosis，treatment modalities，portal vein thrombosis，tumor capsule，UICC stage，thenumber of cancer nodules，pathologic type affect the survival of patients with liver cancerresection independent influencing factors.3..To the low risk of recurrence in patients，thepostoperative adjuvant transcatheter arterial chemoembolization treatment can not improvetheir survival period; For patients with a high risk of recurrence，the postoperative adjuvanttranscatheter arterial chemoembolization treatment can improve the survival of patients.